PHARMING GROUP NV (PHARM.AS) Fundamental Analysis & Valuation

AMS:PHARM • NL0010391025

Current stock price

1.362 EUR
+0.03 (+2.56%)
Last:

This PHARM.AS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PHARM.AS Profitability Analysis

1.1 Basic Checks

  • In the past year PHARM has reported negative net income.
  • PHARM had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: PHARM reported negative net income in multiple years.
  • In multiple years PHARM reported negative operating cash flow during the last 5 years.
PHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFPHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • PHARM has a Return On Assets of 0.56%. This is in the better half of the industry: PHARM outperforms 66.67% of its industry peers.
  • Looking at the Return On Equity, with a value of 1.02%, PHARM is in the better half of the industry, outperforming 70.37% of the companies in the same industry.
  • PHARM has a Return On Invested Capital of 6.27%. This is in the better half of the industry: PHARM outperforms 79.01% of its industry peers.
Industry RankSector Rank
ROA 0.56%
ROE 1.02%
ROIC 6.27%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
PHARM.AS Yearly ROA, ROE, ROICPHARM.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • PHARM's Profit Margin of 0.75% is fine compared to the rest of the industry. PHARM outperforms 67.90% of its industry peers.
  • PHARM's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 8.54%, PHARM is in the better half of the industry, outperforming 76.54% of the companies in the same industry.
  • PHARM's Operating Margin has declined in the last couple of years.
  • PHARM's Gross Margin of 87.91% is fine compared to the rest of the industry. PHARM outperforms 77.78% of its industry peers.
  • PHARM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.54%
PM (TTM) 0.75%
GM 87.91%
OM growth 3Y19.35%
OM growth 5Y-24.92%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
PHARM.AS Yearly Profit, Operating, Gross MarginsPHARM.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PHARM.AS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PHARM is still creating some value.
  • The number of shares outstanding for PHARM has been increased compared to 1 year ago.
  • The number of shares outstanding for PHARM has been increased compared to 5 years ago.
  • The debt/assets ratio for PHARM has been reduced compared to a year ago.
PHARM.AS Yearly Shares OutstandingPHARM.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
PHARM.AS Yearly Total Debt VS Total AssetsPHARM.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of 1.02, we must say that PHARM is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of PHARM (1.02) is comparable to the rest of the industry.
  • PHARM has a debt to FCF ratio of 2.15. This is a good value and a sign of high solvency as PHARM would need 2.15 years to pay back of all of its debts.
  • PHARM has a better Debt to FCF ratio (2.15) than 88.89% of its industry peers.
  • A Debt/Equity ratio of 0.39 indicates that PHARM is not too dependend on debt financing.
  • The Debt to Equity ratio of PHARM (0.39) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Altman-Z 1.02
ROIC/WACC1.12
WACC5.6%
PHARM.AS Yearly LT Debt VS Equity VS FCFPHARM.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • PHARM has a Current Ratio of 2.59. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of PHARM (2.59) is comparable to the rest of the industry.
  • PHARM has a Quick Ratio of 2.03. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.03, PHARM is in line with its industry, outperforming 46.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.03
PHARM.AS Yearly Current Assets VS Current LiabilitesPHARM.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. PHARM.AS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 111.11% over the past year.
  • PHARM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.41% yearly.
  • The Revenue has grown by 26.55% in the past year. This is a very strong growth!
  • The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)111.11%
EPS 3Y-40.82%
EPS 5Y-48.41%
EPS Q2Q%60%
Revenue 1Y (TTM)26.55%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%

3.2 Future

  • The Earnings Per Share is expected to grow by 157.07% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 12.57% on average over the next years. This is quite good.
EPS Next Y1877.6%
EPS Next 2Y329.38%
EPS Next 3Y213.1%
EPS Next 5Y157.07%
Revenue Next Year8.86%
Revenue Next 2Y5.74%
Revenue Next 3Y2.04%
Revenue Next 5Y12.57%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHARM.AS Yearly Revenue VS EstimatesPHARM.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
PHARM.AS Yearly EPS VS EstimatesPHARM.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

Find the best growth stocksShow best growing peers

5

4. PHARM.AS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Forward Earnings ratio is 39.79, which means the current valuation is very expensive for PHARM.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PHARM indicates a somewhat cheap valuation: PHARM is cheaper than 72.84% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of PHARM to the average of the S&P500 Index (23.28), we can say PHARM is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 39.79
PHARM.AS Price Earnings VS Forward Price EarningsPHARM.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • PHARM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PHARM is cheaper than 97.53% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHARM indicates a rather cheap valuation: PHARM is cheaper than 98.77% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 2.03
EV/EBITDA 0.29
PHARM.AS Per share dataPHARM.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PHARM's earnings are expected to grow with 213.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y329.38%
EPS Next 3Y213.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHARM.AS Dividend Analysis

5.1 Amount

  • PHARM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARM.AS Fundamentals: All Metrics, Ratios and Statistics

PHARMING GROUP NV

AMS:PHARM (3/20/2026, 7:00:00 PM)

1.362

+0.03 (+2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners24.69%
Inst Owner ChangeN/A
Ins Owners1.35%
Ins Owner ChangeN/A
Market Cap94.89M
Revenue(TTM)376.10M
Net Income(TTM)2.82M
Analysts88.57
Price Target2.19 (60.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)532.06%
Min EPS beat(2)-6.76%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)286.26%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)81.54%
EPS beat(12)5
Avg EPS beat(12)48.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.68%
Max Revenue beat(2)1.11%
Revenue beat(4)3
Avg Revenue beat(4)5.37%
Min Revenue beat(4)-1.68%
Max Revenue beat(4)13.37%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)7
Avg Revenue beat(12)0.29%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.14%
EPS NQ rev (1m)-95%
EPS NQ rev (3m)-95%
EPS NY rev (1m)51.18%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)0.81%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)-0.34%
Revenue NY rev (3m)4.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 39.79
P/S 0.29
P/FCF 2.03
P/OCF 2
P/B 0.4
P/tB 0.77
EV/EBITDA 0.29
EPS(TTM)0
EYN/A
EPS(NY)0.03
Fwd EY2.51%
FCF(TTM)0.67
FCFY49.21%
OCF(TTM)0.68
OCFY49.9%
SpS4.67
BVpS3.44
TBVpS1.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.56%
ROE 1.02%
ROCE 8.36%
ROIC 6.27%
ROICexc 11.75%
ROICexgc 34.65%
OM 8.54%
PM (TTM) 0.75%
GM 87.91%
FCFM 14.35%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y55.24%
ROICexgc growth 5Y-23.76%
ROICexc growth 3Y34.03%
ROICexc growth 5Y-22.4%
OM growth 3Y19.35%
OM growth 5Y-24.92%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Debt/EBITDA 2.47
Cap/Depr 6.73%
Cap/Sales 0.2%
Interest Coverage 5.18
Cash Conversion 126.22%
Profit Quality 1911.19%
Current Ratio 2.59
Quick Ratio 2.03
Altman-Z 1.02
F-Score6
WACC5.6%
ROIC/WACC1.12
Cap/Depr(3y)6.96%
Cap/Depr(5y)24.22%
Cap/Sales(3y)0.36%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3Y-40.82%
EPS 5Y-48.41%
EPS Q2Q%60%
EPS Next Y1877.6%
EPS Next 2Y329.38%
EPS Next 3Y213.1%
EPS Next 5Y157.07%
Revenue 1Y (TTM)26.55%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%
Revenue Next Year8.86%
Revenue Next 2Y5.74%
Revenue Next 3Y2.04%
Revenue Next 5Y12.57%
EBIT growth 1Y472.59%
EBIT growth 3Y45.97%
EBIT growth 5Y-15.82%
EBIT Next Year4.45%
EBIT Next 3Y48.37%
EBIT Next 5Y57.73%
FCF growth 1Y2182.32%
FCF growth 3Y38.11%
FCF growth 5Y-4.61%
OCF growth 1Y3147.8%
OCF growth 3Y34.55%
OCF growth 5Y-8.14%

PHARMING GROUP NV / PHARM.AS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to PHARM.AS.


What is the valuation status for PHARM stock?

ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.


Can you provide the profitability details for PHARMING GROUP NV?

PHARMING GROUP NV (PHARM.AS) has a profitability rating of 4 / 10.